Skip to main content
AAN.com
Research Article
February 7, 2022
Open Accesscontinuing medical educationLetter to the Editor

Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline

March 29, 2022 issue
98 (13) e1337-e1348
Letters to the Editor
Track CitationsAdd to favorites

Abstract

Background and Objectives

Loneliness is common, and its prevalence is rising. The relationship of loneliness with subsequent dementia and the early preclinical course of Alzheimer disease and related dementia (ADRD) remains unclear. Thus, the primary objective of this study was to determine the association of loneliness with 10-year all-cause dementia risk and early cognitive and neuroanatomic imaging markers of ADRD vulnerability.

Methods

This was a retrospective analysis of prospectively collected data from the population-based Framingham Study cohorts (September 9, 1948–December 31, 2018). Eligible participants had loneliness assessed and were dementia-free at baseline. Loneliness was recorded with the Center for Epidemiologic Studies Depression Scale, defined conservatively as feeling lonely ≥3 days in the past week. The main outcomes were incident dementia over a 10-year period, cognition, and MRI brain volumes and white matter injury.

Results

Of 2,308 participants (mean age 73 [SD 9] years, 56% women) who met eligibility in the dementia sample, 14% (329 of 2,308) developed dementia and 6% (144 of 2,308) were lonely. Lonely (versus not lonely) adults had higher 10-year dementia risk (age-, sex-, and education-adjusted hazard ratio 1.54, 95% CI 1.06–2.24). Lonely participants <80 years of age without APOE ε4 alleles had a 3-fold greater risk (adjusted hazard ratio 3.03, 95% CI, 1.63–5.62). Among 1,875 persons without dementia who met eligibility in the cognition sample (mean age 62 [SD 9] years, 54% women), loneliness associated with poorer executive function, lower total cerebral volume, and greater white matter injury.

Discussion

Over 10 years of close clinical dementia surveillance in this cohort study, loneliness was associated with increased dementia risk; this tripled in adults whose baseline risk would otherwise be relatively low on the basis of age and genetic risk, representing a majority of the US population. Loneliness was also associated with worse neurocognitive markers of ADRD vulnerability, suggesting an early pathogenic role. These findings may have important clinical and public health implications given observed loneliness trends.

Classification of Evidence

This study provides Class I evidence that loneliness increases the 10-year risk of developing dementia.
Loneliness is a risk factor for increased morbidity1 and mortality2 and can be reduced,3 yet its prevalence is rising, from 11% to 14% over a 2-year period extending early into the coronavirus disease 2019 pandemic in a US population–based sample,4 amounting to ≈46 million lonely Americans.5 Estimated loneliness prevalence ranges higher for adults ≥60 years of age in US and international cohorts (13%–43%).6-8 Given observed trends, a notable population health concern is that loneliness, especially if persistent, may be an important risk factor for dementia,6,9,10 but findings have been inconsistent.9,11,12
Cohort studies have associated loneliness with increased risk of cognitive decline,6 dementia,10,13 and Alzheimer disease and related dementia (ADRD) neuropathologic changes.14,15 Other results do not support these associations.9,11,12 Regardless of whether loneliness is an early ADRD contributor, symptom, or both, uncertainty about its association with incident dementia risk could underestimate the impact of increasing loneliness and limit understanding of ADRD development and underlying mechanisms. Estimates of dementia risk related to loneliness could be improved with longitudinal studies with more frequent comprehensive clinical and neuropsychological assessments, neurobiological measures that correspond with preclinical ADRD vulnerability, and continuous surveillance for the clinically important endpoint of dementia in a large population-based sample with long duration of extensive monitoring and minimal loss to follow-up. Thus, we analyzed data from the Framingham Study (FS), one of the largest and longest-running longitudinal cohorts in the United States, to determine how the baseline presence (versus absence) of loneliness in a population-based sample of adults associates with risk of developing dementia and indicators of susceptibility for neurocognitive decline. The primary research question of this study was to evaluate, among younger and older adult age groups, the prospective association of loneliness with 10-year incident dementia (confirmed by rigorous and continuous clinical dementia surveillance with adjudication by a dementia review panel of neurologists and neuropsychologists) and the cross-sectional association of loneliness with early markers of ADRD vulnerability: cognitive function (confirmed by standardized and comprehensive neuropsychological evaluations), brain volumes (confirmed by MRI measures of total cerebral volume and hippocampal volume), and small vessel cerebrovascular injury (confirmed by MRI measure of white matter hyperintensities).

Methods

Samples

This study included FS Original cohort participants attending their 25th biennial examination (1997–1999) and Offspring participants attending their seventh quadrennial examination (1998–2001). For the primary dementia analysis, eligible participants had a loneliness assessment and were at least 60 years of age (participants <60 years of age are unlikely to have substantial 10-year risk of dementia).16 Persons were excluded if they had prevalent dementia or no dementia follow-up. The subsequent analysis evaluated the association of loneliness with early cognitive and neuroimaging indicators of ADRD pathology. Because neuropsychological17 and MRI neuroanatomic18 changes are well known to accompany underlying accumulation of ADRD neuropathologic changes many years before its clinical manifestation as dementia, eligible participants were 40 to 79 years of age and had a loneliness assessment and cognitive testing. Participants were excluded if they had prevalent dementia or stroke. Given our predetermined approach for secondary biological validation with this sample and subsequent results of exploratory interaction analyses, participants were also excluded in this sample if they had no genotypic information or an APOE ε4 allele. Imaging analyses used a subset who also had a brain MRI.

Standard Protocol Approvals, Registrations, and Patient Consents

All participants provided written informed consent. The Institutional Review Board of Boston University Medical Center approved the consent form and study protocol.

Exposure

Methods quantifying loneliness with the Center for Epidemiologic Studies Depression Scale (CES-D)19 in large longitudinal cohorts like FS have previously been described.6,10 In brief, the CES-D asks respondents to report whether each of 20 depressive symptoms was present during the past week “rarely or none of the time (<1 day)” (0 points), “some or a little of the time (1–2 days)” (1 point), “occasionally or a moderate amount of time (3–4 days)” (2 points), or “most or all of the time (5–7 days)” (3 points). Identical to similar cohort studies that used the CES-D item asking how often the respondent felt lonely,6,10 participants were classified as lonely (3–7 days) or not lonely (0–2 days). This approach has yielded both positive and null results in similar community-based cohorts of older adults, and positive associations have demonstrated a pattern similar to exposure-response relationships whereby participants who have more severe and persistent loneliness are more likely to have greater ADRD risk.6,10
Although instruments assessing burden of depressive symptoms like the CES-D include items that ask about feelings of loneliness because of their co-occurrence,19 there is growing consensus that depression and loneliness are conceptually separate constructs that are statistically separable,6,20 represent distinct clinical phenomena,21 involve distinct brain circuitry,22,23 and have associations with ADRD neuropathologic changes that are independent from one another14,15,24 and, in this context, have limited to at most moderate overlap.6,10 However, because loneliness (as a predisposing variable in depression) has been observed to have consistently moderate effects on depressive symptoms across studies regardless of sampling strategies, publication type, and publication year,25 the CES-D loneliness item was selected as the main exposure variable while still accounting for depressive symptoms as a potential confounder with a modified version of the CES-D.

Incident Dementia Assessment

The primary outcome was clinical diagnosis of incident all-cause dementia during a 10-year follow-up period after baseline examination. The rigorous and continuous FS dementia surveillance methods have been published previously.26 In brief, cognitive status has been monitored with Mini-Mental State Examination27 and neuropsychological testing since 1975 in the Original cohort and since 1987 in the Offspring cohort. A dementia review panel of study neurologists and neuropsychologists reviewed every possible dementia case and determined the diagnosis date using extensive data such as serial and prompted assessments, telephone interviews with family/caregivers, and medical records.26 Diagnosis of dementia is based on criteria including the DSM-IV.28 Cases detected before 2001 had repeat reviews after 2001 so that updated diagnostic criteria could be applied. Continuous dementia surveillance occurred through December 31, 2018.

Cognitive Assessment

Clinic examination attendees had standardized neuropsychological testing administered by trained research assistants and neuropsychologists after clinical evaluation. Tests performed are reliable, are widely used, and cover all domains of the Alzheimer's Disease Center's Uniform Data Set.29 For the present study, we selected 3 separate measures to analyze that reflect key cognitive processes commonly affected early in ADRD17: Logical Memory Delayed Recall (memory), Trails Making Test B Minus A (executive function), and global cognition. For global cognition, we used a global cognitive score that was developed on a data sample collected at Offspring examination 7 with principal component analysis forcing a single component solution. The tasks included in the principal component analysis are the following: Trails Making Test A, Trails Making Test B, Logical Memory (Immediate and Delayed Recall), Visual Reproductions (Immediate and Delayed Recall), Paired Associate Learning (Delayed Recall), Hooper Visual Organization Test, and Similarities Test.30 The global cognitive score is a weighted sum of standardized scores; higher scores represent better performance. This method is identical to previous studies, is useful in addressing the neuropathologic and clinical heterogeneity of all-cause dementia in community-based samples of older adults,31 and is described in further detail elsewhere.32 Its creation is summarized in eTable 1, links.lww.com/WNL/B792.

Brain MRI Assessment

Preclinical ADRD MRI measures restricted only to cortical subregions might be less sensitive to the full range of underlying ADRD neuropathology in a population-based sample33; thus, our imaging analyses used the following key measures most likely to represent early ADRD cerebral vulnerability in the form of atrophy or microangiopathic white matter injury: total cerebral volume, hippocampal volume, and white matter hyperintensities. Participants were scanned during the baseline examination period with a Siemens Magnetom MRI (1.5T; Siemens Healthineers, Erlangen, Germany). Full details of acquisition, image analysis, and quantification of MRI variables have been described elsewhere, including imaging parameters and sequences, measurement protocols, segmentation methods, reliability, and reproducibility.34 Volume measures were corrected for head size by use of the ratio of each measure over total cranial volume multiplied by 100.34,35 All MRI variables were standardized in analyses. Additional details of imaging acquisition and quantification methods are provided in eMethods, links.lww.com/WNL/B792.

Covariates

Educational achievement was assessed with a 4-level variable (no high school degree, high school degree only, some college, college degree or more). Additional adjustments for depressive symptoms, social isolation, antidepressant medication use, and common vascular risk factors were performed in secondary sensitivity analyses. Regarding depressive symptoms, a re-evaluation of the factor structure of the original CES-D36 used a factor solution of 3 factors (somatic symptoms, negative affect, anhedonia) and demonstrated that, although the loneliness item was retained as a measure of negative affect, the weight of the loneliness item was the lowest within this factor and was relatively consistent across diverse participants, including undergraduate, community, rehabilitation, and clinical samples, as well as an epidemiologic sample comparable to the FS cohorts. Thus, depressive symptoms were accounted for with a modified CES-D score; it excluded the loneliness item, summed points for remaining questions (range 0–57 points), and was a continuous log-transformed variable to account for nonnormal distribution.37 Regarding social isolation, the self-reported Berkman-Syme Social Network Index was used to control for social isolation on the basis of social network size.1 Identical to prior methods,38,39 the Social Network Index classified individuals according to summed score cutoffs as socially isolated (0–1 points) or not socially isolated (2–4 points).
For interaction analyses, APOE ε4 allele carrier status was included as an independent genetic covariate instead of a polygenic risk score given its greater clinical and epidemiologic utility for considering the role of genetic predisposition in the present study.40 APOE genotype was determined by isoelectric focusing of collected plasma and confirmed by DNA genotype.41

Statistical Analysis

To characterize age differences in the association of loneliness with dementia risk, the primary dementia analysis was performed for the entire sample and stratified by age group: <80 and ≥80 years of age. The decision to characterize age differences by stratifying the sample at 80 years of age was made a priori and based on knowledge of extant literature reporting associations of loneliness with greater cortical amyloid and regional tau accumulation using PET imaging,14,15 previous FS investigations suggesting that loneliness-related dementia risk10,39 and risk of neurocognitive markers of early ADRD vulnerability42 varied between younger and older adults, and loneliness prevalence estimates demonstrating a slight increase by age for young-old adults (age 65–79 years) and a more notable increase for oldest-old adults ≥80 years of age.43
For the primary dementia analysis, overall and by age, Cox proportional hazards regression models estimated age-, sex-, and education-adjusted hazard ratios for 10-year dementia risk comparing participants who were lonely with those who were not lonely. To systematically assess for effect modification, interactions were evaluated using Cox models with interaction terms for each of the following variables by loneliness: sex, education level, and APOE ε4 status. Then, stratified Cox regression models were performed as indicated by significant interaction terms. The proportional hazards assumption was upheld for reported models, assessed by analyzing Schoenfeld residuals.
To characterize the role of loneliness in early ADRD susceptibility before the onset of dementia, a second sample was derived that was based on significant age-group-by-modifier subsets in the dementia analysis. The new sample consisted of participants who had neuropsychological testing at the baseline evaluation; most had a baseline brain MRI obtained. We used adjusted multivariable linear regression models in this second sample to assess whether loneliness status was an independent predictor of selected neurocognitive measures. All models adjusted for age, age2, sex, educational achievement, and time interval from loneliness assessment to when the cognitive or MRI measure was acquired. β Coefficient estimates were expressed in SD units (SDU), so each 1-unit change corresponds to a SD difference in each measure.
For sensitivity analysis, the primary dementia, cognition, and imaging models (model 1) were additionally adjusted in sequential models to account for baseline depressive symptoms (model 2), social isolation (Model 3), antidepressant medication use (model 4), and vascular risk factors (model 5). Participants with missing covariate data were excluded from these sensitivity analyses. To investigate the possibility that loneliness is a very early ADRD symptom (rather than an ADRD potentiator), we examined primary dementia models after excluding persons with prevalent mild cognitive impairment; separately, we also delayed the follow-up period to begin 5 years after baseline and to span 5 years, allowing a more conservative assessment of the role of loneliness before ADRD clinical expression. Additional sensitivity analyses used a 3-level ordinal term for loneliness in the primary dementia, cognition, and imaging models. To evaluate risk by dementia subtype, we used the primary dementia models to separately assess risk of developing Alzheimer disease and vascular dementia.
Statistical significance was determined with a 2-sided α level of 0.05 without appropriate indication to correct for multiple comparisons given that each planned comparison tested a different specific hypothesis in the main analyses of the present study.44 Exploratory interaction analyses in the dementia sample used an α level of 0.10 to increase sensitivity, consistent with prior FS studies assessing effect modification.45 Analyses were performed with SAS 9.4 (SAS Institute Inc, Cary, NC). This study followed Strengthening the Reporting of Observational Studies in Epidemiology reporting guidelines (eMethods, links.lww.com/WNL/B792).

Data Availability

The FS datasets analyzed for the present study are available through formal data-use agreements. Any investigator may access the data through the process outlined on the FS website (framinghamheartstudy.org).

Results

Association of Loneliness and 10-Year Risk of Incident Dementia

In the dementia analytic sample, 2,308 participants (576 Original and 1732 Offspring members) met inclusion criteria (Figure 1A). Mean age was 73 years (SD, 9 years); 56% were women; and 53% had at least some college education (Table 1). Participants ≥80 years of age were more likely to have prevalent cardiovascular disease and no college degree. At baseline, almost all Mini-Mental State Examination scores were in the cognitively unimpaired range (median score 29 [interquartile range 27–30], range 15–30). Twenty percent of participants had at least 1 APOE ε4 allele. Age-based subgroups had similar social network size and low depressive symptoms. The prevalence of participants reporting loneliness at least 1 day in the past week—452 of 2,308 (20%)—was comparable to that of similar cohorts of older adults.6-8,46,47 Overall, 144 of 2,308 (6%) participants felt lonely ≥3 days in the past week.
Figure 1 Sample Derivation
Sample derivation flow diagrams for the Framingham Heart Study participants in the (A) dementia and (B) cognition analytic samples.
Table 1 Sample Characteristics
During the 10-year follow-up period (median 10.00 [interquartile range 5.50–10.00] years), 329 of 2,308 (14%) participants were diagnosed with dementia (189 Original and 140 Offspring members). Thirty-one of 144 (22%) lonely participants developed dementia. In the overall dementia sample, after adjustment for age, sex, and educational achievement, loneliness was significantly associated with higher dementia incidence (hazard ratio 1.54, 95% CI 1.06–2.24) (Table 2 and Figure 2A). There was no significant association between loneliness and incident dementia in participants ≥80 years of age; however, among participants <80 years of age, those who were lonely were more than twice as likely to develop dementia (hazard ratio 2.27, 95% CI 1.32–3.91). In the subsequent assessment of effect modification in the younger group, an interaction with APOE ε4 status was identified (Table 2). Loneliness was associated with a 3-fold increased hazard of incident dementia in the younger group of participants who did not carry an APOE ε4 allele (hazard ratio 3.03, 95% CI 1.63–5.62) (Figure 2B).
Table 2 Adjusted 10-Year Risk of Incident All-Cause Dementia by Loneliness Status
Figure 2 Ten-Year Cumulative Incidence of Dementia by Loneliness Status
Cumulative incidence curves for the primary outcome, 10-year incident all-cause dementia (A) overall and (B) for the subgroup of participants 60 to 79 years of age without an APOE ε4 allele. Median follow-up time for lonely participants was 5.94 (interquartile range 2.90–10.00) years; for participants who were not lonely, 10.00 (interquartile range, 5.89–10.00) years. HR = hazard ratio; NA = not available.

Association of Loneliness With Early Cognitive and Neuroanatomic Markers of ADRD Vulnerability

To better understand the relationship between loneliness and ADRD vulnerability in dementia-free adults, we used the cognition sample that consisted of 1,875 participants who met inclusion criteria (41 Original and 1834 Offspring members) (Figure 1B). Mean age was 62 years (SD 9 years); 54% were women; and 67% had at least some college education (Table 1). Loneliness was associated with poorer cognition in the executive function domain; lonely participants scored 0.23 SDU lower than participants who were not lonely (Table 3). A subset of the cognition sample was used to examine the relationship between loneliness and neuroanatomic measures. Baseline brain MRI was obtained for 1,643 of 1,875 (88%) participants (Figure 1B). The MRI subset also excluded 32 participants who had other neurologic conditions; the remaining 1,611 participants were representative of the full cognition sample (Table 1). Lonely (versus not lonely) participants were more likely to have lower total cerebral volume and greater white matter hyperintensity burden. Lonely participants had total cerebral volumes that were 0.25 SDU lower and white matter hyperintensity volumes that were 0.28 SDU greater (Table 3). There were no significant associations between loneliness and the global cognitive score, Logical Memory Delayed Recall score, or hippocampal volume.
Table 3 Multivariable-Adjusted Models of Cognitive and Neuroanatomic Measures as a Function of Loneliness Status: Participants 40 to 79 Years of Age Without an APOE ε4 Allele

Sensitivity Analysis

Primary findings in the dementia analysis persisted after excluding 88 participants with baseline mild cognitive impairment (hazard ratio 1.92, 95% CI 1.29–2.85) and after advancing follow-up by 5 years (hazard ratio 1.83, 95% CI 1.08–3.12). Loneliness remained consistently associated for the younger group (including the APOE ε4-negative subset) after additional adjustments for depressive symptoms, social isolation, antidepressant medication use, and common vascular risk factors (eTable 2, links.lww.com/WNL/B792). Similarly, loneliness was still associated with greater white matter hyperintensities after additional adjustments (eTable 3). The magnitude of the association between loneliness and total cerebral volume reduced with adjustment for social isolation. Loneliness was no longer associated with cognition after adjustment for depressive symptoms. Using an ordinal term for loneliness in primary models produced similar results overall (eTables 4 and 5) except that reporting loneliness 1 to 2 d/wk in the older age group was also associated with increased dementia risk. In an examination of the association of loneliness with incidence of separate dementia subtypes, loneliness was associated with dementia due to Alzheimer disease. The association was not observed for dementia due to vascular dementia, although the hazard ratio remained in the expected direction (eTable 6).

Classification of Evidence

The primary research question of this study was to evaluate, among younger and older adult age groups, the prospective association of loneliness with 10-year incident dementia (confirmed by rigorous and continuous clinical dementia surveillance with adjudication by a dementia review panel of neurologists and neuropsychologists) and the cross-sectional association of loneliness with early markers of ADRD vulnerability: cognitive function (confirmed by standardized and comprehensive neuropsychological evaluations), brain volumes (confirmed by MRI measures of total cerebral volume and hippocampal volume), and small vessel cerebrovascular injury (confirmed by MRI measure of white matter hyperintensities). This study provides Class I evidence that loneliness increases the 10-year risk of developing dementia.

Discussion

This cohort study found that loneliness was associated with an increased 10-year incidence of all-cause dementia, reaffirming the elevated dementia risk of loneliness demonstrated by others9,12 but also revealing a tripling in risk for lonely adults <80 years of age without an APOE ε4 allele. This association between loneliness and 10-year dementia risk may be at least partly due to the involvement of loneliness in the earliest stages of ADRD neuropathogenesis, as suggested by our subsequent findings characterizing how loneliness in dementia-free adults relates to early cognitive and imaging measures of ADRD vulnerability. Among APOE ε4–negative adults <80 years of age, the highest-risk subgroup identified, loneliness was associated with (1) poorer executive function (a cognitive domain that includes processes such as attention, judgment, organization, planning, and decision-making), (2) lower total cerebral volume (a global neuroanatomic measure that is often more sensitive to the broad range of neuropathologies underlying cognitive decline in population-based samples than only cortical subregions),33 and (3) a greater volume of white matter hyperintensities (indicating greater extent of small vessel cerebrovascular injury). Taken together, these results implicate reporting loneliness ≥3 days in the past week as an important potentially modifiable psychosocial factor for middle-aged and young-old APOE ε4–negative adults early in the ADRD neuropathologic process leading up to the clinical presentation and diagnosis of dementia.
Although our results were consistent with the direction of prior associations reported between loneliness and dementia in population-based samples of older adults,9,12,13 the estimated risk of incident dementia in younger APOE ε4–negative participants was much higher than in other studies. For example, our estimate was greater than the 40% increased dementia risk found in the Health and Retirement Study among comparable lonely individuals ≥65 years of age who were also followed up for 10 years but had their cognitive status assessed with 3 tasks from a brief telephone interview designed for screening dementia.13 It is notable that our findings are also consistent with a recent FS study using only Offspring cohort participant data that observed that persistent loneliness in midlife (defined as reporting loneliness ≥1 day in the past week at the sixth and seventh quadrennial examinations) was associated with higher lifetime risk of dementia and Alzheimer disease (dementia hazard ratio 1.91, 95% CI 1.25–2.90).10 This risk with persistent loneliness was similarly elevated for APOE ε4 noncarriers (hazard ratio 2.32, 95% CI 1.49–3.62), although not as high as the 3-fold risk increase observed in the present study of loneliness reported at a single time point, at baseline, which may have clinical and public health relevance for brief screening assessments of risk. Compared to prior studies, the risk estimates in our investigation may be due to a combination of larger sample size, different loneliness assessments and definitions, parsimonious approach to enhancing sensitivity with the use of high-risk subgroups, longer follow-up period, and follow-up beginning at a time when individuals–based on age–were more likely to develop dementia in subsequent years. Although loneliness was measured with a single-item assessment from an instrument originally designed to evaluate depressive symptoms, our findings reasonably suggest that the increased dementia risk observed in lonely adults may be due to related increases in early ADRD vulnerability through pathways involving multifocal brain atrophy, extensive microvascular injury, and consequent cognitive decline.
Whether loneliness is an early symptom of neurodegenerative disease or an early contributor to neuropathology and cognitive decline remains unclear. On the one hand, if we consider loneliness as an early symptom of neurodegeneration, the present findings may reflect the earliest manifestations of cortical β-amyloid14 and tau15 accumulation in brain areas that both are affected early in the course of ADRD and are involved in the perception of loneliness and other neurobehavioral functions.23 On the other hand, if loneliness is mainly a causal factor in cognitive decline, the present findings may be indicative of loneliness driving (or compounding) vascular, neuroendocrine, inflammatory, and cytotoxic injury biological pathways that have been proposed to be specific to the distress of loneliness21 or increased functional communication in neural systems implicated in generating one's perception of loneliness (e.g., the default mode network).23 Regardless, although the present study is observational, it supports an upstream contributory role for loneliness given that participants without dementia were followed up for 10 years, which is longer than might typically be expected for dementia to develop if mild cognitive or neurobehavioral symptoms were present due to underlying ADRD pathologic changes. This was additionally supported by sensitivity analyses conducted to assess for the potential of reverse causality.
Our finding that lonely young-old adults without the APOE ε4 allele had elevated dementia risk may be due to APOE ε4 carriers having a higher genetic load for ADRD, so loneliness may not have been as influential in determining dementia risk. Loneliness also might have had a role in reducing APOE ε2 and ε3 expression through proposed stress and immune dysregulation pathways,48 leading to lower APOE in blood and the brain and consequently greater susceptibility to β-amyloid aggregation and ADRD pathogenesis. Moreover, the absent association between loneliness and dementia among individuals >80 years of age may be attributable to loneliness having a less prominent role in ADRD when other age-related biological factors account for a greater proportion of incident dementia after 80 years of age (e.g., tauopathy, TAR DNA-binding protein 43 proteinopathy, arteriosclerosis, and hippocampal sclerosis).49 Thus, for younger individuals without inherent genetic risk factors, loneliness and related psychosocial determinants of health may be more influential than traditional ADRD clinical risk factors, acting through pathways independent of or compounding biology.
Overall, these results have implications for dementia risk stratification, the relevance of basic loneliness screening, and the potential to underestimate dementia risk in lonely young-old adults without known genetic risk factors. As the proportion of lonely adults increases within societies, so does the potential to underestimate the associated risk of developing dementia. The current study observed not only a robust independent relationship among loneliness, incident dementia, and early ADRD vulnerability but also a notably higher risk for a specific subgroup that includes the estimated 61% of Black adults and 74% of White adults in the United States who do not possess an APOE ε4 allele.50 One of the strengths of neurologists and other health care providers is a broad perspective of the biological, clinical, and public health implications of the present findings, as well as an appreciation for the value of interdisciplinary strategies to address loneliness. These results raise the importance of future studies to further investigate mechanisms, possible interventions, and tools to efficiently screen for loneliness in routine clinical care (e.g., asking the question used in this study: In the past week, how often have you felt lonely?).
A strength of the present analysis is the rich data source including 2 distinct but similar cohorts followed up over many decades with minimal loss to follow-up. To minimize potential bias from unmeasured confounding that could influence loneliness patterns over time, analyses accounted for baseline differences between cohorts and other factors that could simultaneously affect loneliness and dementia risk or loneliness and ADRD-related neurocognitive measures.
Like other studies using data from the FS Original and Offspring cohorts, this sample is composed of mostly White individuals. Although the sample was smaller than in some prior studies,13 it was large enough to address the questions of interest and in a cohort with comprehensive follow-up spanning >6 decades. Although information on additional symptoms related to loneliness was not available for participants and was not included (e.g., feeling left out or misunderstood), the loneliness item of the CES-D is sufficiently distinct from the other CES-D items that the possibility of substantial overlap with depression or confounding from depressive symptoms that may manifest differently across age groups and various phenotypes of depression was likely low to moderate.36 Thus, this approach was considered to be adequate and appropriate. Although loneliness was slightly more prevalent in the older age group (consistent with similar community-based samples of older adults),6-8,46 it remains possible that depression without loneliness had a more influential role than loneliness without depression in this age group. Although the possibility for reverse causality cannot be ruled out in this cohort study (i.e., our findings could have been the result of underlying ADRD neuropathology manifesting as feelings of loneliness years or decades before clinical diagnosis), studying causal relationships between loneliness and incident dementia is not readily suitable for randomized clinical trials, and hence, conclusions may rely on cohort studies.
In this cohort study, loneliness was associated with higher 10-year risk of incident dementia; notably, lonely APOE ε4–negative younger adults had a 3-fold increased risk. This elevated risk is possibly due to associations identified between loneliness and early cognitive and neuroanatomic markers of ADRD vulnerability, raising potential population health implications for observed trends in loneliness.

Glossary

ADRD
Alzheimer disease and related dementia
CES-D
Center for Epidemiologic Studies Depression Scale
DSM-IV
Diagnostic and Statistical Manual of Mental Disorders, 4th edition
FS
Framingham Study
SDU
SD units

Acknowledgment

The authors are grateful to the FS participants who have committed so much of their time and effort.

Appendix Authors

Footnotes

See page e1406
Class of Evidence: NPub.org/coe

References

1.
Valtorta NK, Kanaan M, Gilbody S, Ronzi S, Hanratty B. Loneliness and social isolation as risk factors for coronary heart disease and stroke: systematic review and meta-analysis of longitudinal observational studies. Heart. 2016;102(13):1009-1016.
2.
Rico-Uribe LA, Caballero FF, Martin-Maria N, Cabello M, Ayuso-Mateos JL, Miret M. Association of loneliness with all-cause mortality: a meta-analysis. PLoS One. 2018;13:e0190033.
3.
Masi CM, Chen HY, Hawkley LC, Cacioppo JT. A meta-analysis of interventions to reduce loneliness. Pers Soc Psychol Rev. 2011;15(3):219-266.
4.
McGinty EE, Presskreischer R, Han H, Barry CL. Psychological distress and loneliness reported by US adults in 2018 and April 2020. JAMA. 2020;324(1):93-94.
5.
Population and housing unit estimates. Accessed September 23. census.gov/programs-surveys/popest.html
6.
Donovan NJ, Wu Q, Rentz DM, Sperling RA, Marshall GA, Glymour MM. Loneliness, depression and cognitive function in older U.S. adults. Int J Geriatr Psychiatry. 2017;32(5):564-573.
7.
Perissinotto CM, Stijacic Cenzer I, Covinsky KE. Loneliness in older persons: a predictor of functional decline and death. Arch Intern Med. 2012;172(14):1078-1083.
8.
Victor CR, Yang K. The prevalence of loneliness among adults: a case study of the United Kingdom. J Psychol. 2012;146:85-104.
9.
Wilson RS, Krueger KR, Arnold SE, et al. Loneliness and risk of Alzheimer disease. Arch Gen Psychiatry. 2007;64(2):234-240.
10.
Akhter-Khan SC, Tao Q, Ang TFA, et al. Associations of loneliness with risk of Alzheimer's disease dementia in the Framingham Heart Study. Alzheimers Dement. 2021;17(10):1619-1627.
11.
Penninkilampi R, Casey AN, Singh MF, Brodaty H. The association between social engagement, loneliness, and risk of dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2018;66(4):1619-1633.
12.
Lara E, Martin-Maria N, De la Torre-Luque A, et al. Does loneliness contribute to mild cognitive impairment and dementia? A systematic review and meta-analysis of longitudinal studies. Ageing Res Rev. 2019;52:7-16.
13.
Sutin AR, Stephan Y, Luchetti M, Terracciano A. Loneliness and risk of dementia. J Gerontol B Psychol Sci Soc Sci. 2020;75(7):1414-1422.
14.
Donovan NJ, Okereke OI, Vannini P, et al. Association of higher cortical amyloid burden with loneliness in cognitively normal older adults. JAMA Psychiatry. 2016;73(12):1230-1237.
15.
d'Oleire Uquillas F, Jacobs HIL, Biddle KD, et al. Regional tau pathology and loneliness in cognitively normal older adults. Transl Psychiatry. 2018;8:282.
16.
Chêne G, Beiser A, Au R, et al. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimers Dement. 2015;11(3):310-320.
17.
Monsell SE, Mock C, Hassenstab J, et al. Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology. 2014;83(5):434-440.
18.
Kaur B, Himali JJ, Seshadri S, et al. Association between neuropathology and brain volume in the Framingham Heart Study. Alzheimer Dis Assoc Disord. 2014;28:219-225.
19.
Radloff LS. The CES-D scale a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
20.
Cacioppo S, Capitanio JP, Cacioppo JT. Toward a neurology of loneliness. Psychol Bull. 2014;140(6):1464-1504.
21.
Kumar A, Salinas J. The long-term public health impact of social distancing on brain health: topical review. Int J Environ Res Public Health. 2021;18(14):7307.
22.
Padmanabhan JL, Cooke D, Joutsa J, et al. A human depression circuit derived from focal brain lesions. Biol Psychiatry. 2019;86(10):749-758.
23.
Spreng RN, Dimas E, Mwilambwe-Tshilobo L, et al. The default network of the human brain is associated with perceived social isolation. Nat Commun. 2020;11(1):6393.
24.
Gonzales MM, Samra J, O'Donnell A, et al. Association of midlife depressive symptoms with regional amyloid-beta and tau in the Framingham Heart Study. J Alzheimers Dis. 2021;82:249-260.
25.
Erzen E, Çikrikci Ö. The effect of loneliness on depression: a meta-analysis. Int J Soc Psychiatry. 2018;64(5):427-435.
26.
Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med. 2016;374(6):523-532.
27.
Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
28.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. American Psychiatric Association; 1994.
29.
Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009;23:91-101.
30.
Wechsler D. WAIS-R : Wechsler Adult Intelligence Scale-Revised. Psychological Corp; 1981:1981.
31.
Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab. 2016;36(1):172-186.
32.
Pase MP, Beiser A, Enserro D, et al. Association of ideal cardiovascular health with vascular brain injury and incident dementia. Stroke. 2016;47(5):1201-1206.
33.
Farias ST, Mungas D, Reed B, et al. Maximal brain size remains an important predictor of cognition in old age, independent of current brain pathology. Neurobiol Aging. 2012;33(8):1758-1768.
34.
Albert M, Massaro J, DeCarli C, et al. Profiles by sex of brain MRI and cognitive function in the Framingham Offspring Study. Alzheimer Dis Assoc Disord. 2010;24:190-193.
35.
Fletcher E, Singh B, Harvey D, Carmichael O, DeCarli C. Adaptive image segmentation for robust measurement of longitudinal brain tissue change. Annu Int Conf IEEE Eng Med Biol Soc. 2012;2012:5319-5322.
36.
Carleton RN, Thibodeau MA, Teale MJ, et al. The Center for Epidemiologic Studies Depression Scale: a review with a theoretical and empirical examination of item content and factor structure. PLoS One. 2013;8(3):e58067.
37.
Vilagut G, Forero CG, Barbaglia G, Alonso J. Screening for depression in the general population with the Center for Epidemiologic Studies Depression (CES-D): a systematic review with meta-analysis. PLoS One. 2016;11(5):e0155431.
38.
Loucks EB, Sullivan LM, D'Agostino RB, Larson MG, Berkman LF, Benjamin EJ. Social networks and inflammatory markers in the Framingham heart study. J Biosoc Sci. 2006;38(6):835-842.
39.
Salinas J, Beiser A, Himali JJ, et al. Associations between social relationship measures, serum brain-derived neurotrophic factor, and risk of stroke and dementia. Alzheimers Dement. 2017;3:229-237.
40.
Ware EB, Faul JD, Mitchell CM, Bakulski KM. Considering the APOE locus in Alzheimer's disease polygenic scores in the Health and Retirement Study: a longitudinal panel study. BMC Med Genomics. 2020;13(1):164.
41.
Welty FK, Lahoz C, Tucker KL, Ordovas JM, Wilson PW, Schaefer EJ. Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the Framingham Offspring population. Arterioscler Thromb Vasc Biol. 1998;18(11):1745-1751.
42.
Salinas J, O'Donnell A, Kojis DJ, et al. Association of social support with brain volume and cognition. JAMA Netw Open. 2021;4(8):e2121122.
43.
Dykstra PA. Older adult loneliness: myths and realities. Eur J Ageing. 2009;6(2):91-100.
44.
Ruxton GD, Beauchamp G. Time for some a priori thinking about post hoc testing. J Behav Ecol. 2008;19:690-693.
45.
Nishtala A, Piers RJ, Himali JJ, et al. Atrial fibrillation and cognitive decline in the Framingham heart study. Heart Rhythm. 2018;15:166-172.
46.
Theeke LA. Predictors of loneliness in U.S. adults over age sixty-five. Arch Psychiatr Nurs. 2009;23(5):387-396.
47.
Cudjoe TKM, Roth DL, Szanton SL, Wolff JL, Boyd CM, Thorpe RJ. The epidemiology of social isolation: National Health and Aging Trends study. J Gerontol B Psychol Sci Soc Sci. 2020;75(1):107-113.
48.
Hayley S, Hakim AM, Albert PR. Depression, dementia and immune dysregulation. Brain. 2021;144(3):746-760.
49.
Nelson PT, Trojanowski JQ, Abner EL, et al. New old pathologies: AD, PART, and cerebral age-related TDP-43 with sclerosis (CARTS). J Neuropathol Exp Neurol. 2016;75:482-498.
50.
Rajan KB, Barnes LL, Wilson RS, et al. Racial differences in the association between apolipoprotein E risk alleles and overall and total cardiovascular mortality over 18 years. J Am Geriatr Soc. 2017;65(11):2425-2430.
Letters to the Editor
28 July 2022
Reader Response: Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline
Tomoyuki Kawada, Professor| Nippon Medical School

Salinas et al. reported that the adjusted hazard ratio (HR) of loneliness for 10-year all-cause dementia significantly increased.1 Interestingly, a threefold increase of 10-year dementia risk was observed in lonely participants under 80 years of age without APOE ε4 alleles. APOE ε4 alleles are a genetic risk for dementia in general, but loneliness overrode the advantage of no APOE ε4 alleles for dementia.

Perceived social isolation or loneliness is a comorbid symptom of patients with subjective cognitive decline or mild cognitive impairment.2 In addition, loneliness was closely related to biological markers associated with Alzheimer's disease, such as amyloid and tau burden.3 In contrast, Shen et al. reported that the adjusted HR (95% confidence interval) of loneliness for dementia was 1.04 (0.94-1.16).4 The relationship between social isolation and loneliness should be specified by considering sex, age, socioeconomic status, and genetic factors.

Further, older adults who experience social isolation and a homebound lifestyle are less likely to access medical care, which might lead to serious health problems.5 Progression of dementia would also be closely related to subsequent social isolation; thus, a bidirectional relationship between loneliness and dementia should be considered for the analysis.

Disclosure

The author reports no relevant disclosures. Contact [email protected] for full disclosures.  

References

  1. Salinas J, Beiser AS, Samra JK, et al. Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline. Neurology. 2022;98(13):e1337-e1348. doi:10.1212/WNL.0000000000200039
  2. Zhang Y, Tatewaki Y, Liu Y, et al. Perceived social isolation is correlated with brain structure and cognitive trajectory in Alzheimer's disease. Geroscience. 2022;44(3):1563-1574. doi:10.1007/s11357-022-00584-6
  3. Lam JA, Murray ER, Yu KE, et al. Neurobiology of loneliness: a systematic review. Neuropsychopharmacology. 2021;46(11):1873-1887. doi:10.1038/s41386-021-01058-7
  4. Shen C, Rolls E, Cheng W, et al. Associations of Social Isolation and Loneliness With Later Dementia [published online ahead of print, 2022 Jun 8]. Neurology. 2022;10.1212/WNL.0000000000200583.
  5. Mitsutake S, Koike T, Ishizaki T, et al. Influence of co-existing social isolation and homebound status on medical care utilization and expenditure among older adults in Japan. Arch Gerontol Geriatr. 2021;93:104286. doi:10.1016/j.archger.2020.104286
15 April 2022
Author Response: Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline
Joel Salinas, Neurologist| NYU Grossman School of Medicine

We greatly appreciate the comment on our findings.1 It is true that the associations of loneliness and frailty with increased dementia risk raise important questions that merit further exploration. We have begun to explore this by examining these longitudinal associations in the HAALSI cohort, which is composed of predominantly Black older adults from rural South Africa.2 Although associations of loneliness are identified with notable neuroanatomical measures (lower total cerebral volume and greater white matter injury) in our present study, this was a cross-sectional analysis and would benefit from further validation. The temporal relationships of these pathways are worth exploring further, especially given prior cross-sectional evidence from the Harvard Aging Brain Study identifying associations between greater levels of loneliness and greater accumulation of cortical amyloid and right entorhinal tau on PET imaging.3,4 We agree that, in light of studies that continue to provide evidence that supports the relevance of these pathways, there needs to be further action against loneliness and social isolation through targeted interventions that address the psychosocial determinants of brain health.

Disclosure

The authors report no relevant disclosures. Contact [email protected] for full disclosures.  

References

  1. Salinas J, Beiser AS, Samra JK, et al. Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline [published online ahead of print, 2022 Feb 7]. Neurology. 2022;10.1212/WNL.0000000000200039.
  2. Bassil DT, Farrell MT, Wagner RG, et al. Cohort Profile Update: Cognition and dementia in the Health and Aging in Africa Longitudinal Study of an INDEPTH community in South Africa (HAALSI dementia) [published online ahead of print, 2021 Dec 6]. Int J Epidemiol. 2021;dyab250. doi:10.1093/ije/dyab250
  3. Donovan NJ, Okereke OI, Vannini P, et al. Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. JAMA Psychiatry. 2016;73(12):1230-1237. doi:10.1001/jamapsychiatry.2016.2657
  4. d'Oleire Uquillas F, Jacobs HIL, Biddle KD, et al. Regional tau pathology and loneliness in cognitively normal older adults. Transl Psychiatry. 2018;8(1):282. Published 2018 Dec 18. doi:10.1038/s41398-018-0345-x
8 February 2022
Reader Response: Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline
Timothy Daly, Philosophy of Science| Sorbonne Université

There are striking parallels between Salinas and colleagues’ recent finding that older adults who described feeling lonely three or more days a week had a greater 10-year risk of developing dementia1 and the report by Wallace et al. of a strong 10-year link between frailty and increased dementia risk.2 In other words, research shows that individuals with dementia tend to have been lonely or frail in the decade prior to developing the condition.

These are, of course, interesting scientific findings worthy of further exploration. For example, Salinas and colleagues could study longitudinal changes in loneliness and their correlation with neuroanatomical imaging measures or neuropathological burden, as Wallace et al. did with frailty. Moreover, the relationship between loneliness and frailty could be studied. But there is a far more pressing issue: loneliness can be avoided, with a broad range of individual and society-wide measures.3 Furthermore, the Covid-19 pandemic increased loneliness across generations, particularly in people with lower income.4 This makes the need for action against loneliness all the more urgent, as part of a larger struggle against the social determinants of brain health.5 Otherwise, dementia risk will continue to reflect our increasingly unequal society.

Disclosure

The author reports no relevant disclosures. Contact [email protected] for full disclosures.  

References

  1. Salinas J, Beiser AS, Samra JK, et al. Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline [published online ahead of print, 2022 Feb 7]. Neurology. 2022;10.1212/WNL.0000000000200039.
  2. Wallace LMK, Theou O, Godin J, et al. 10-year frailty trajectory is associated with Alzheimer's dementia after considering neuropathological burden. Aging Med (Milton). 2021;4(4):250-256. Published 2021 Dec 15. doi:10.1002/agm2.12187
  3. Fakoya OA, McCorry NK, Donnelly M. Loneliness and social isolation interventions for older adults: a scoping review of reviews. BMC Public Health. 2020;20(1):129. Published 2020 Feb 14. doi:10.1186/s12889-020-8251-6
  4. McQuaid RJ, Cox SML, Ogunlana A, Jaworska N. The burden of loneliness: Implications of the social determinants of health during COVID-19. Psychiatry Res. 2021;296:113648. doi:10.1016/j.psychres.2020.113648
  5. Röhr S. Social determinants of brain health need to be addressed in risk reduction of cognitive decline and dementia. Int Psychogeriatr. 2021;33(12):1249-1251. doi:10.1017/S104161022100260X

Information & Authors

Information

Published In

Neurology®
Volume 98Number 13March 29, 2022
Pages: e1337-e1348
PubMed: 35131906

Publication History

Received: June 24, 2021
Accepted: December 27, 2021
Published online: February 7, 2022
Published in print: March 29, 2022

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Study Funding

This research was supported by the Boston University School of Medicine, Harvard Medical School, the Henry and Allison McCance Center for Brain Health, the Massachusetts General Hospital, and the New York University Grossman School of Medicine; contracts from the National Heart, Lung, and Blood Institute (N01-HC 25195, HHSN268201500001I, 75N92019D00031); grants from the National Institute on Neurological Disorders and Stroke (NS017950, UH2NS100605, T32NS048005) and National Institute on Aging [AG049505, AG052409, AG054076, AG049607, AG059421, K23AG057760]; and the Robert Katzman Research Training Fellowship in Alzheimer's and Dementia Research cosponsored by the American Academy of Neurology, the American Brain Foundation, and the Alzheimer's Association.

Authors

Affiliations & Disclosures

Joel Salinas, MD, MBA, MSc*
From the Department of Neurology (J.S.), Center for Cognitive Neurology, New York University Grossman School of Medicine, New York; The Framingham Study (J.S., A.S.B., J.K.S., A.O., H.J.A., S.S.); Department of Biostatistics (A.S.B., J.K.S., A.O.), Boston University School of Public Health; Department of Neurology (A.S.B., H.J.A., S.S.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), University of California Davis; and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (M.M.G., S.S.), University of Texas Health Sciences Center, San Antonio.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
<br>Eisai Co., consultation on a topic not related to the present <br>study.<br> Signature: Joel Salinas Date: 11/29/2021<br><br>
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Alexa S. Beiser, PhD*
From the Department of Neurology (J.S.), Center for Cognitive Neurology, New York University Grossman School of Medicine, New York; The Framingham Study (J.S., A.S.B., J.K.S., A.O., H.J.A., S.S.); Department of Biostatistics (A.S.B., J.K.S., A.O.), Boston University School of Public Health; Department of Neurology (A.S.B., H.J.A., S.S.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), University of California Davis; and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (M.M.G., S.S.), University of Texas Health Sciences Center, San Antonio.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
<br>Brooks Cole, Introductory Applied Statistics, 2005<br>
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
<br>NIH/NINDS, biostatistician, 2 R01 NS017950-28, 2009-2014 <br><br>NIH/NIA, biostatistician, 5 R01 AG08122, 2005-2010 <br><br>NIH/NIA, biostatistician, 2 R01 AG16495, 2005-2010 <br><br>NIA/NINDS, biostatistician, 1 R01 AG033040-01, 2009-2013<br><br>NIH/NHLBI, biostatistician, R01 HL093029-01A1, 2009-2011<br> Signature: /Alexa Beiser/ Date: 11/29/21<br><br>
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jasmeet K. Samra, BA
From the Department of Neurology (J.S.), Center for Cognitive Neurology, New York University Grossman School of Medicine, New York; The Framingham Study (J.S., A.S.B., J.K.S., A.O., H.J.A., S.S.); Department of Biostatistics (A.S.B., J.K.S., A.O.), Boston University School of Public Health; Department of Neurology (A.S.B., H.J.A., S.S.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), University of California Davis; and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (M.M.G., S.S.), University of Texas Health Sciences Center, San Antonio.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Adrienne O'Donnell, BA
From the Department of Neurology (J.S.), Center for Cognitive Neurology, New York University Grossman School of Medicine, New York; The Framingham Study (J.S., A.S.B., J.K.S., A.O., H.J.A., S.S.); Department of Biostatistics (A.S.B., J.K.S., A.O.), Boston University School of Public Health; Department of Neurology (A.S.B., H.J.A., S.S.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), University of California Davis; and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (M.M.G., S.S.), University of Texas Health Sciences Center, San Antonio.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Charles S. DeCarli, MD
From the Department of Neurology (J.S.), Center for Cognitive Neurology, New York University Grossman School of Medicine, New York; The Framingham Study (J.S., A.S.B., J.K.S., A.O., H.J.A., S.S.); Department of Biostatistics (A.S.B., J.K.S., A.O.), Boston University School of Public Health; Department of Neurology (A.S.B., H.J.A., S.S.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), University of California Davis; and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (M.M.G., S.S.), University of Texas Health Sciences Center, San Antonio.
Disclosure
Scientific Advisory Boards:
1.
<br>1) Novartis Pharmaceuticals<br>
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
<br>1)Novartis Pharmaceuticals<br>
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
<br>National Institutes of Health<br> Signature: /Charles DeCarli/ Date: 11/22/2021<br><br>
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Mitzi M. Gonzales, PhD
From the Department of Neurology (J.S.), Center for Cognitive Neurology, New York University Grossman School of Medicine, New York; The Framingham Study (J.S., A.S.B., J.K.S., A.O., H.J.A., S.S.); Department of Biostatistics (A.S.B., J.K.S., A.O.), Boston University School of Public Health; Department of Neurology (A.S.B., H.J.A., S.S.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), University of California Davis; and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (M.M.G., S.S.), University of Texas Health Sciences Center, San Antonio.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
<br>1) Alzheimer's Association International Conference (AAIC) <br>2021 travel fellowship, travel reimbursement was provided for <br>conference attendance<br>
Editorial Boards:
1.
<br>1) Journal of Alzheimer's Disease, Associate editor, 2022<br>
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
<br>1) NIH Scientific Review Group honorarium, serving on study <br>section in 2021<br>
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
<br>1) NIH/NIA, P30AG066546, Clinical Core Leader, 2021-2026<br>2) NIH/NINDS, U19NS120384, Co-I, 2021-2026<br>3) NIH/NIA, 2R44AG060855, PI (multi-PI), 2021-2023<br>4) NIH/NIA, U24AG059624, co-I, 2021-2023<br>5) UTHSCSA Clinical Translational Science Pilot Award, PI, <br>2020-2022<br>6) UTHSCSA Stevens Parkinson’s Disease Center Pilot Award, <br>PI, 2020-2021<br>7) UTHSCSA Center for Biomedical Neuroscience Pilot Award, <br>PI, 2019-2021<br>8) Texas Alzheimer’s Research and Care Consortium, 2018-28-<br>81-J1, PI 2019-2021<br>
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
<br>1) Alzheimer's Drug Discovery Foundation, GC-201908-2019443 <br>2) Alzheimer's Association Part of Cloud Gates, PTCG-20-695184<br> Stock/Stock Options, Medical Equipment & Materials: <br>1) My husband and I own stock in Abbvie<br>2) My husband and I own stock in Abiomed<br>3) My husband and I own stock in Abbott Laboratories <br>4) My husband and I own stock in Intuitive Surgical <br>5) My husband and I own stock in Eli Lily<br>6) My husband and I own stock in Johnson & Johnson<br>7) My husband and I own stock in Moderna<br> Signature: MITZI GONZALES Date: 11/22/2021<br><br>
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Hugo J. Aparicio, MD, MPH
From the Department of Neurology (J.S.), Center for Cognitive Neurology, New York University Grossman School of Medicine, New York; The Framingham Study (J.S., A.S.B., J.K.S., A.O., H.J.A., S.S.); Department of Biostatistics (A.S.B., J.K.S., A.O.), Boston University School of Public Health; Department of Neurology (A.S.B., H.J.A., S.S.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), University of California Davis; and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (M.M.G., S.S.), University of Texas Health Sciences Center, San Antonio.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
<br>(1) NIH grant R01-AG054076-02S1 (role: diversity supplement <br>awardee; 2016-2020) <br>(2) NIH Loan Repayment Program L30 NS093634 (role: awardee; <br>2014-2021).<br>
Research Support, Academic Entities:
1.
<br>(1) Boston University’s Aram V. Chobanian Assistant <br>Professorship<br>
Research Support, Foundations and Societies:
1.
<br>(1) American Academy of Neurology Career Development Award<br>(2) Alzheimer’s Association Research Grant (AARGD-20-685362)<br> Signature: /Hugo Aparicio/ Date: 11/24/21<br><br>
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sudha Seshadri, MD
From the Department of Neurology (J.S.), Center for Cognitive Neurology, New York University Grossman School of Medicine, New York; The Framingham Study (J.S., A.S.B., J.K.S., A.O., H.J.A., S.S.); Department of Biostatistics (A.S.B., J.K.S., A.O.), Boston University School of Public Health; Department of Neurology (A.S.B., H.J.A., S.S.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), University of California Davis; and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (M.M.G., S.S.), University of Texas Health Sciences Center, San Antonio.
Disclosure
Scientific Advisory Boards:
1.
<br>Steering Committee of the Cardiovascular Health Study; Senate of German <br>Center for Neurodegenerative Diseases (DZNE)<br>
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
<br>Editorial Board of Stroke and Alzheimer's and Dementia<br>
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
<br>Consulted for Biogen<br>
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
<br>NIA AG033040, AG049607,AG058464, AG059421, AG063507<br>AG054076, AG052409, AG058589, AG066524<br><br>NINDS NS017950, NS100605<br>
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
<br>Alzheimer Association grant<br> Signature: /Sudha Seshadri/ Date: 12/01/2021
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Salinas [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
*
These authors contributed equally to this work as first authors.
The Article Processing Charge was funded by the authors.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. “Telephone Angels” Against Loneliness: Experimental Evaluation of the Effectiveness of Telephone Partnerships with Older Adults, Journal of Gerontological Social Work, (1-22), (2025).https://doi.org/10.1080/01634372.2025.2450210
    Crossref
  2. The deprivation cascade hypothesis of dementia, Aging and Health Research, 5, 1, (100219), (2025).https://doi.org/10.1016/j.ahr.2024.100219
    Crossref
  3. Loneliness Modulates Inflammation to Affect the Neurocognitive Function of Older Adults, PsychoNeuroImmunology, (459-492), (2025).https://doi.org/10.1007/978-3-031-73061-0_14
    Crossref
  4. Association of Loneliness with Functional and Cognitive Status in Minor and Major Neurocognitive Disorders, Life, 14, 10, (1216), (2024).https://doi.org/10.3390/life14101216
    Crossref
  5. Contributions of loneliness to cognitive impairment and dementia in older adults are independent of other risk factors and Alzheimer’s pathology: a narrative review, Frontiers in Human Neuroscience, 18, (2024).https://doi.org/10.3389/fnhum.2024.1380002
    Crossref
  6. Association between loneliness and cognitive function, and brain volume in community-dwelling elderly, Frontiers in Aging Neuroscience, 16, (2024).https://doi.org/10.3389/fnagi.2024.1389476
    Crossref
  7. Association of Loneliness with Functional Connectivity MRI, Amyloid-β PET, and Tau PET Neuroimaging Markers of Vulnerability for Alzheimer’s Disease, Journal of Alzheimer’s Disease, 99, 4, (1473-1484), (2024).https://doi.org/10.3233/JAD-231425
    Crossref
  8. Relationship between Loneliness and Mild Behavioral Impairment: Validation of the Japanese Version of the MBI Checklist and a Cross-Sectional Study, Journal of Alzheimer’s Disease, 97, 4, (1951-1960), (2024).https://doi.org/10.3233/JAD-230923
    Crossref
  9. Masala, The National Medical Journal of India, 36, (279-280), (2024).https://doi.org/10.25259/NMJI_670_2023
    Crossref
  10. The Best of Two Worlds to Promote Healthy Cognitive Aging: Definition and Classification Approach of Hybrid Physical Training Interventions, JMIR Aging, 7, (e56433), (2024).https://doi.org/10.2196/56433
    Crossref
  11. See more
Loading...

View Options

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

View Short Form

Full Text

View Full Text
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

Figures

Tables

Media

Share

Share

Share article link

Share